المؤلفون: Parsel, S M, Grandis, J R, Thomas, S M

المصدر: Oncogene ; volume 35, issue 25, page 3217-3226 ; ISSN 0950-9232 1476-5594

مصطلحات موضوعية: Cancer Research, Genetics, Molecular Biology

الإتاحة: https://doi.org/10.1038/onc.2015.424Test
https://www.nature.com/articles/onc2015424.pdfTest
https://www.nature.com/articles/onc2015424Test

المؤلفون: Cheng, S., Feng, H., Lopez, G. Y., Kim, C. K., Duncan, C. G., Alvarez, A., Nishikawa, R., Nagane, M., Su, A.-J., Auron, P. E., Hedberg, M. L., Wang, L., Grandis, J. R., McLendon, R. E., Bigner, D. D., Nakano, I., Joshi, K., Kim, S., Lin, H.-K., Furnari, F. B., Cavenee, W. K., Hu, B., Yan, H., Cheng, S.-Y.

المصدر: Neuro-Oncology ; volume 16, issue suppl 3, page iii16-iii17 ; ISSN 1522-8517 1523-5866

مصطلحات موضوعية: Cancer Research, Neurology (clinical), Oncology

الإتاحة: https://doi.org/10.1093/neuonc/nou206.60Test
http://academic.oup.com/neuro-oncology/article-pdf/16/suppl_3/iii16/3803435/nou206.60.pdfTest

المؤلفون: Argiris, A., Kotsakis, A. P., Hoang, T., Worden, F. P., Savvides, P., Gibson, M. K., Gyanchandani, R., Blumenschein, G. R., Chen, H. X., Grandis, J. R., Harari, P. M., Kies, M. S., Kim, S.

مصطلحات موضوعية: head and neck cancer

الوصف: Background We evaluated combined targeting with cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in squamous cell carcinoma of the head and neck (SCCHN). Patients and methods The combination was studied in human endothelial cells and head and neck and lung cancer xenograft model systems. Patients with recurrent or metastatic SCCHN were treated with weekly cetuximab and bevacizumab, 15 mg/kg on day 1 given intravenously every 21 days, until disease progression. Analysis of tumor biomarkers and related serum cytokines was performed. Results Cetuximab plus bevacizumab enhanced growth inhibition both in vitro and in vivo , and resulted in potent reduction in tumor vascularization. In the clinical trial, 46 eligible patients were enrolled. The objective response rate was 16% and the disease control rate 73%. The median progression-free survival and overall survival were 2.8 and 7.5 months, respectively. Grade 3–4 adverse events were expected and occurred in less than 10% of patients. transforming growth factor alpha, placenta-derived growth factor, EGFR, VEGFR2 increased and VEGF decreased after treatment but did not correlate with treatment efficacy. Conclusions Cetuximab and bevacizumab are supported by preclinical observations and are well tolerated and active in previously treated patients with SCCHN.

وصف الملف: text/html

العلاقة: http://annonc.oxfordjournals.org/cgi/content/short/24/1/220Test; http://dx.doi.org/10.1093/annonc/mds245Test

الإتاحة: https://doi.org/10.1093/annonc/mds245Test
http://annonc.oxfordjournals.org/cgi/content/short/24/1/220Test

المؤلفون: Sok, J C, Lee, J A, Dasari, S, Joyce, S, Contrucci, S C, Egloff, A M, Trevelline, B K, Joshi, R, Kumari, N, Grandis, J R, Thomas, S M

المصدر: British Journal of Cancer ; volume 109, issue 12, page 3049-3056 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/bjc.2013.624Test
http://www.nature.com/articles/bjc2013624.pdfTest
http://www.nature.com/articles/bjc2013624Test

المؤلفون: Panupinthu, N, Yu, S, Zhang, D, Zhang, F, Gagea, M, Lu, Y, Grandis, J R, Dunn, S E, Lee, H Y, Mills, G B

المصدر: Oncogene ; volume 33, issue 22, page 2846-2856 ; ISSN 0950-9232 1476-5594

مصطلحات موضوعية: Cancer Research, Genetics, Molecular Biology

الإتاحة: https://doi.org/10.1038/onc.2013.259Test
https://www.nature.com/articles/onc2013259.pdfTest
https://www.nature.com/articles/onc2013259Test

المؤلفون: Argiris, A., Kotsakis, A. P., Hoang, T., Worden, F. P., Savvides, P., Gibson, M. K., Gyanchandani, R., Blumenschein, G. R., Chen, H. X., Grandis, J. R., Harari, P. M., Kies, M. S., Kim, S.

مصطلحات موضوعية: Original article

الوصف: Background We evaluated combined targeting with cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in squamous cell carcinoma of the head and neck (SCCHN). Patients and methods The combination was studied in human endothelial cells and head and neck and lung cancer xenograft model systems. Patients with recurrent or metastatic SCCHN were treated with weekly cetuximab and bevacizumab, 15 mg/kg on day 1 given intravenously every 21 days, until disease progression. Analysis of tumor biomarkers and related serum cytokines was performed. Results Cetuximab plus bevacizumab enhanced growth inhibition both in vitro and in vivo , and resulted in potent reduction in tumor vascularization. In the clinical trial, 46 eligible patients were enrolled. The objective response rate was 16% and the disease control rate 73%. The median progression-free survival and overall survival were 2.8 and 7.5 months, respectively. Grade 3–4 adverse events were expected and occurred in less than 10% of patients. transforming growth factor alpha, placenta-derived growth factor, EGFR, VEGFR2 increased and VEGF decreased after treatment but did not correlate with treatment efficacy. Conclusions Cetuximab and bevacizumab are supported by preclinical observations and are well tolerated and active in previously treated patients with SCCHN.

وصف الملف: text/html

العلاقة: http://annonc.oxfordjournals.org/cgi/content/short/mds245v2Test; http://dx.doi.org/10.1093/annonc/mds245Test

الإتاحة: https://doi.org/10.1093/annonc/mds245Test
http://annonc.oxfordjournals.org/cgi/content/short/mds245v2Test

المؤلفون: Argiris, A., Karamouzis, M. V., Smith, R., Kotsakis, A., Gibson, M. K., Lai, S. Y., Kim, S., Branstetter, B. F., Shuai, Y., Romkes, M., Wang, L., Grandis, J. R., Ferris, R. L., Johnson, J. T., Heron, D. E.

مصطلحات موضوعية: original article

الوصف: Background: We studied the combination of pemetrexed, a multi-targeted antifolate, and cetuximab, an mAb against the epidermal growth factor receptor, with radiotherapy in poor prognosis head and neck cancer. Patients and methods: Patients received pemetrexed on days 1, 22, and 43 on a dose-escalation scheme with starting level (0) 350 mg/m2 (level −1, 200 mg/m2; level +1, 500 mg/m2) with concurrent radiotherapy (2 Gy/day) and cetuximab in two separate cohorts, not previously irradiated (A) and previously irradiated (B), who received 70 and 60–66 Gy, respectively. Genetic polymorphisms of thymidylate synthase and methylenetetrahydrofolate reductase were evaluated. Results: Thirty-two patients were enrolled. The maximum tolerated dose of pemetrexed was 500 mg/m2 in cohort A and 350 mg/m2 in cohort B. Prophylactic antibiotics were required. In cohort A, two dose-limiting toxicities (DLTs) occurred (febrile neutropenia), one each at levels 0 and +1. In cohort B, two DLTs occurred at level +1 (febrile neutropenia; death from perforated duodenal ulcer and sepsis). Grade 3 mucositis was common. No association of gene polymorphisms with toxicity or efficacy was evident. Conclusion: The addition of pemetrexed 500 mg/m2 to cetuximab and radiotherapy is recommended for further study in not previously irradiated patients.

وصف الملف: text/html

العلاقة: http://annonc.oxfordjournals.org/cgi/content/short/mdr002v1Test; http://dx.doi.org/10.1093/annonc/mdr002Test

الإتاحة: https://doi.org/10.1093/annonc/mdr002Test
http://annonc.oxfordjournals.org/cgi/content/short/mdr002v1Test

المؤلفون: Passero, V. A., Branstetter, B. F., Shuai, Y., Heron, D. E., Gibson, M. K., Lai, S. Y., Kim, S. W., Grandis, J. R., Ferris, R. L., Johnson, J. T., Argiris, A.

مصطلحات موضوعية: original article

الوصف: Purpose: RECIST have limitations when applied to potentially curable locally advanced squamous cell carcinoma of the head and neck (SCCHN). [18F]fluorodeoxyglucose–positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome. Patients and methods: We studied patients with previously untreated stages III–IVb SCCHN treated with primary concurrent chemoradiotherapy on five prospective clinical trials. Response was assessed by clinical exam, computed tomography (CT), and PET portions of combined PET–CT scan ∼8 weeks after completion of chemoradiotherapy. Results: Fifty-three patients were analyzed. Complete response (CR) was demonstrated in 42 patients (79%) by clinical exam, 15 (28%) by CT, and 27 (51%) by PET. CR as assessed by PET, but not as assessed by clinical exam or CT using RECIST, correlated significantly with progression-free status (PFS) ( P < 0.0001). The 2-year PFS for patients with CR and without CR by PET was 93% and 48%, respectively ( P = 0.0002). Conclusions: A negative PET scan on combined PET–CT after chemoradiotherapy is a powerful predictor of outcome in patients receiving curative chemoradiotherapy for SCCHN. PET–CT is indicated for response evaluation in this setting to improve the accuracy of post-treatment assessment by CT.

وصف الملف: text/html

العلاقة: http://annonc.oxfordjournals.org/cgi/content/short/mdq226v1Test; http://dx.doi.org/10.1093/annonc/mdq226Test

الإتاحة: https://doi.org/10.1093/annonc/mdq226Test
http://annonc.oxfordjournals.org/cgi/content/short/mdq226v1Test

المؤلفون: Wheeler, S E, Suzuki, S, Thomas, S M, Sen, M, Leeman-Neill, R J, Chiosea, S I, Kuan, C-T, Bigner, D D, Gooding, W E, Lai, S Y, Grandis, J R

المصدر: Oncogene ; volume 29, issue 37, page 5135-5145 ; ISSN 0950-9232 1476-5594

مصطلحات موضوعية: Cancer Research, Genetics, Molecular Biology

الإتاحة: https://doi.org/10.1038/onc.2009.279Test
https://www.nature.com/articles/onc2009279.pdfTest
https://www.nature.com/articles/onc2009279Test

المؤلفون: Langevin, S. M., Stone, R. A., Bunker, C. H., Grandis, J. R., Sobol, R. W., Taioli, E.

المصدر: Carcinogenesis ; volume 31, issue 5, page 864-870 ; ISSN 0143-3334 1460-2180

مصطلحات موضوعية: Cancer Research, General Medicine

الإتاحة: https://doi.org/10.1093/carcin/bgq051Test
http://academic.oup.com/carcin/article-pdf/31/5/864/7520087/bgq051.pdfTest